Attached files
file | filename |
---|---|
10-K - FORM 10-K - ALPHARX INC | alpharx120209f10k.htm |
EX-32.2 - EXHIBIT 32.2 - ALPHARX INC | alpharx120209exh322.htm |
EX-32.1 - EXHIBIT 32.1 - ALPHARX INC | alpharx120209exh321.htm |
EX-31.2 - EXHIBIT 31.2 - ALPHARX INC | alpharx120209exh312.htm |
EXHIBIT 31.1
I, Michael Lee, President and Chief Executive Officer of AlphaRx, certify that:
1.
I have reviewed this annual report on Form 10-K of AlphaRx, Inc.;
2.
Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
3.
Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:
a) designed such disclosure controls
and procedures to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to me by others within
those entities, particularly during the period in which this annual report is
being prepared;
b) evaluated the effectiveness of the registrant's
disclosure controls and procedures as of a date within 90 days prior to the
filing date of this annual report (the Evaluation Date); and
c)
presented in this annual report my conclusions about the effectiveness of the
disclosure controls and procedures based on my evaluation as of the Evaluation
Date;
5.
We have disclosed, based on my most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
a) all significant deficiencies in the
design or operation of internal controls which could adversely affect the
registrant's ability to record, process, summarize and report financial data and
have identified for the registrant's auditors any material weaknesses in
internal controls; and
b) any fraud, whether or not material, that
involves management or other employees who have a significant role in the
registrant's internal controls; and
6.
I have indicated in this annual report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of my most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.
Date: December 4, 2009
/s/ Michael Lee
Michael
Lee, President and Chief Executive Officer